Abstract
Phosphoinositide 3-kinase (PI3K), a key regulator in the PI3K/AKT/mT0R signaling pathway, plays a critical role in regulation of cell growth, differentiation, metastasis apoptosis, and angiogenesis processes. Abnormal activation of PI3K is closely related to the development of many types of human cancers. PI3K8 is an important isoform of PI3K family, mainly expressed in leukocytes, which makes it an attractive target for the treatment of hematological malignancies. Great efforts in both industry and academia have been made to develop PI3K8 selective inhibitors as anti-cancer agents. This review attempts to provide an overview of recent advances in the research of PI3K8 selective inhibitors, fueling the progress of the ideal selective PI3KS inhibitors in the future.
| Original language | English |
|---|---|
| Pages (from-to) | 503-510 |
| Number of pages | 8 |
| Journal | Journal of China Pharmaceutical University |
| Volume | 47 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Advance
- Hematological malignancies
- Inhibitors
- PI3K8
Fingerprint
Dive into the research topics of 'Advances in PI3K8 selective inhibitors'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver